Developing a Liquid Biopsy Collection and Repository Program at Princess Margaret Cancer Centre for Patients With Solid Tumors or Blood Cancers and High-Risk Individuals

What this Trial Is About

Researchers are developing a liquid biopsy protocol at the University Health Networks Princess Margaret Cancer Centre. This observational study focuses on collecting blood samples and archived tumor specimens from patients with confirmed solid tumors, hematological cancers, or those at high risk for cancer due to genetic predisposition or family history. The goal is to enable non-invasive monitoring of tumor progression and treatment response using circulating cell-free nucleic acids such as DNA and RNA. Participants will provide peripheral blood samples, called liquid biopsies, at multiple points during their disease course. These samples will be used for future research to better understand cancer behavior and treatment effects. The study includes patients with various cancers including breast, lung, colon, ovarian, melanoma, lymphoma, leukemia, and others. There is a single observational arm named LIBERATE. During the study, researchers will collect and annotate biospecimens over a period of up to five years. Participants will also complete electronic consent and correlative studies questionnaires throughout this time. No interventions or treatments are administered as part of the study. The data collected aims to provide diagnostic and prognostic information, helping inform future cancer research and care.

Liquid Biopsy Evaluation and Repository Development at Princess Margaret